Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer EvolveImmune's ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Beyond logos, create business cards, social media kits, favicons, and more. Download high-resolution PNG, JPEG, and vector files, and get brand guidelines for fonts and colors. Make unlimited changes ...

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $ ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...

NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...